Larimar Therapeutics Inc (NAS:LRMR)

$ 6.57 -0.19 (-2.81%) Market Cap: 419.21 Mil Enterprise Value: 232.99 Mil PE Ratio: 0 PB Ratio: 2.11 GF Score: 36/100

Larimar Therapeutics Inc To Provide a Program Update Transcript
Feb 12, 2024
Larimar Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023
Larimar Therapeutics Inc To Discuss Phase 2 dose exploration trial of CTI-1601 Transcript
Jul 25, 2023
Larimar Therapeutics Inc CTI-1601 May 2023 Program Update Conference Call Transcript
May 15, 2023
Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 04, 2023
9Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Immunology and Neurology Day Transcript
Nov 15, 2022
Larimar Therapeutics Inc To Discuss Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Transcript
Sep 14, 2022
Larimar Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Q1 2021 Larimar Therapeutics Inc Earnings Call Transcript
May 11, 2021

$8.36 (-36.28%)

Earnings
Zafgen Inc and Chondrial Therapeutics Announce Definitive Merger Agreement - M&A Call Transcript
Dec 18, 2019
Q4 2018 Zafgen Inc Earnings Call Transcript
Mar 11, 2019

Earnings

Larimar Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript

Jul 15, 2021 / 07:00PM GMT

Release Date Price: $10.41 (-0.95%)

Transcript

Myles Minter

William Blair & Company LLC - Analyst

Good afternoon, and welcome back to the William Blair Biotech Focus Conference of 2021. This is one of the last sessions of the day -- last but not least. So my name is Myles Minter, I'm a senior biotech analyst here at the firm covering neurosciences and other areas. Before we get started on this fireside chat with Larimar Therapeutics, I will refer you to disclosures available on williamblair.com just in case there is any forward-looking statements being made today. In addition to that, there is a question-and-answer box below. If you submit your questions there, I will do my best to get them addressed throughout the chat today.

With those formalities out of the way, it is my pleasure to introduce Carole Ben-Maimon, who is the CEO of Larimar Therapeutics -- Chondrial prior to the Zafgen merger as well. So welcome and thank you very much for joining us today, Carole. I guess for just all the listeners on the call, the majority, I believe, will be familiar with the story. But for those who aren't, can you just give us an update on the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.